ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

BackgroundThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus a...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International journal of gynecological cancer Ročník 31; číslo 12; s. 1589 - 1594
Hlavní autoři:	Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States BMJ Publishing Group Ltd 01.12.2021 Elsevier Inc by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology BMJ Publishing Group
Témata:	Antineoplastic Combined Chemotherapy Protocols - administration & dosage BRCA1 protein BRCA2 protein Carcinoma, Ovarian Epithelial - drug therapy Clinical Trial Double-Blind Method Female homologous recombination Humans Indoles - administration & dosage Maintenance Chemotherapy - methods Nivolumab - administration & dosage ovarian neoplasms Ovarian Neoplasms - drug therapy Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage BRCA2 protein ovarian neoplasms homologous recombination BRCA1 protein
ISSN:	1048-891X, 1525-1438, 1525-1438
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	BackgroundThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus active surveillance. Furthermore, preclinical and early clinical studies have shown that PARP inhibitors and immune checkpoint inhibitors have synergistic antitumor activity and may provide an additional therapeutic option for patients in this population.Primary ObjectivesIn women with newly diagnosed ovarian, fallopian tube, or peritoneal cancer, we wish to assess the efficacy of frontline maintenance treatment with the PARP inhibitor rucaparib versus placebo following response to platinum-based chemotherapy (ATHENA–MONO), and to assess the combination of rucaparib plus nivolumab (a programmed death receptor 1 (PD-1)–blocking monoclonal antibody) versus rucaparib alone (ATHENA–COMBO).Study Hypothesis(1) Maintenance therapy with rucaparib monotherapy may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting. (2) The combination of nivolumab plus rucaparib may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting compared with rucaparib alone.Trial DesignATHENA is an international, randomized, double-blind, phase III trial consisting of two independent comparisons (ATHENA–MONO and ATHENA–COMBO) in patients with newly diagnosed platinum-sensitive ovarian cancer. Patients are randomized 4:4:1:1 to the following: oral rucaparib+ intravenous nivolumab (arm A); oral rucaparib + intravenous placebo (arm B); oral placebo+ intravenous nivolumab (arm C); and oral placebo + intravenous placebo (arm D). The starting dose of rucaparib is 600 mg orally twice a day and nivolumab 480 mg intravenously every 4 weeks. ATHENA–MONO compares arm B with arm D to evaluate rucaparib monotherapy versus placebo, and ATHENA–COMBO evaluates arm A versus arm B to investigate the effects of rucaparib and nivolumab in combination versus rucaparib monotherapy. ATHENA–MONO and ATHENA–COMBO share a common treatment arm (arm B) but each comparison is independently powered.Major Inclusion/Exclusion CriteriaPatients ≥18 years of age with newly diagnosed advanced, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer who have achieved a response after completion of cytoreductive surgery and initial platinum-based chemotherapy are enrolled. No other prior treatment for ovarian cancer, other than the frontline platinum regimen, is permitted.Primary EndpointThe primary endpoint is investigator-assessed progression-free survival by Response Evaluation Criteria in Solid Tumors v1.1.Sample SizeApproximately 1000 patients have been enrolled and randomized.Estimated Dates for Completing Accrual and Presenting ResultsThe trial completed accrual in 2020. While dependent on event rates, primary results of ATHENA–MONO are anticipated in early 2022 and results of ATHENA–COMBO are anticipated to mature at a later date.Trial RegistrationThis trial is registered at clinicaltrials.gov (NCT03522246).
AbstractList	The optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus active surveillance. Furthermore, preclinical and early clinical studies have shown that PARP inhibitors and immune checkpoint inhibitors have synergistic antitumor activity and may provide an additional therapeutic option for patients in this population.BACKGROUNDThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus active surveillance. Furthermore, preclinical and early clinical studies have shown that PARP inhibitors and immune checkpoint inhibitors have synergistic antitumor activity and may provide an additional therapeutic option for patients in this population.In women with newly diagnosed ovarian, fallopian tube, or peritoneal cancer, we wish to assess the efficacy of frontline maintenance treatment with the PARP inhibitor rucaparib versus placebo following response to platinum-based chemotherapy (ATHENA-MONO), and to assess the combination of rucaparib plus nivolumab (a programmed death receptor 1 (PD-1)-blocking monoclonal antibody) versus rucaparib alone (ATHENA-COMBO).PRIMARY OBJECTIVESIn women with newly diagnosed ovarian, fallopian tube, or peritoneal cancer, we wish to assess the efficacy of frontline maintenance treatment with the PARP inhibitor rucaparib versus placebo following response to platinum-based chemotherapy (ATHENA-MONO), and to assess the combination of rucaparib plus nivolumab (a programmed death receptor 1 (PD-1)-blocking monoclonal antibody) versus rucaparib alone (ATHENA-COMBO).(1) Maintenance therapy with rucaparib monotherapy may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting. (2) The combination of nivolumab plus rucaparib may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting compared with rucaparib alone.STUDY HYPOTHESIS(1) Maintenance therapy with rucaparib monotherapy may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting. (2) The combination of nivolumab plus rucaparib may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting compared with rucaparib alone.ATHENA is an international, randomized, double-blind, phase III trial consisting of two independent comparisons (ATHENA-MONO and ATHENA-COMBO) in patients with newly diagnosed platinum-sensitive ovarian cancer. Patients are randomized 4:4:1:1 to the following: oral rucaparib+ intravenous nivolumab (arm A); oral rucaparib + intravenous placebo (arm B); oral placebo+ intravenous nivolumab (arm C); and oral placebo + intravenous placebo (arm D). The starting dose of rucaparib is 600 mg orally twice a day and nivolumab 480 mg intravenously every 4 weeks. ATHENA-MONO compares arm B with arm D to evaluate rucaparib monotherapy versus placebo, and ATHENA-COMBO evaluates arm A versus arm B to investigate the effects of rucaparib and nivolumab in combination versus rucaparib monotherapy. ATHENA-MONO and ATHENA-COMBO share a common treatment arm (arm B) but each comparison is independently powered.TRIAL DESIGNATHENA is an international, randomized, double-blind, phase III trial consisting of two independent comparisons (ATHENA-MONO and ATHENA-COMBO) in patients with newly diagnosed platinum-sensitive ovarian cancer. Patients are randomized 4:4:1:1 to the following: oral rucaparib+ intravenous nivolumab (arm A); oral rucaparib + intravenous placebo (arm B); oral placebo+ intravenous nivolumab (arm C); and oral placebo + intravenous placebo (arm D). The starting dose of rucaparib is 600 mg orally twice a day and nivolumab 480 mg intravenously every 4 weeks. ATHENA-MONO compares arm B with arm D to evaluate rucaparib monotherapy versus placebo, and ATHENA-COMBO evaluates arm A versus arm B to investigate the effects of rucaparib and nivolumab in combination versus rucaparib monotherapy. ATHENA-MONO and ATHENA-COMBO share a common treatment arm (arm B) but each comparison is independently powered.Patients ≥18 years of age with newly diagnosed advanced, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer who have achieved a response after completion of cytoreductive surgery and initial platinum-based chemotherapy are enrolled. No other prior treatment for ovarian cancer, other than the frontline platinum regimen, is permitted.MAJOR INCLUSION/EXCLUSION CRITERIAPatients ≥18 years of age with newly diagnosed advanced, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer who have achieved a response after completion of cytoreductive surgery and initial platinum-based chemotherapy are enrolled. No other prior treatment for ovarian cancer, other than the frontline platinum regimen, is permitted.The primary endpoint is investigator-assessed progression-free survival by Response Evaluation Criteria in Solid Tumors v1.1.PRIMARY ENDPOINTThe primary endpoint is investigator-assessed progression-free survival by Response Evaluation Criteria in Solid Tumors v1.1.Approximately 1000 patients have been enrolled and randomized.SAMPLE SIZEApproximately 1000 patients have been enrolled and randomized.The trial completed accrual in 2020. While dependent on event rates, primary results of ATHENA-MONO are anticipated in early 2022 and results of ATHENA-COMBO are anticipated to mature at a later date.ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTSThe trial completed accrual in 2020. While dependent on event rates, primary results of ATHENA-MONO are anticipated in early 2022 and results of ATHENA-COMBO are anticipated to mature at a later date.This trial is registered at clinicaltrials.gov (NCT03522246).TRIAL REGISTRATIONThis trial is registered at clinicaltrials.gov (NCT03522246). The optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus active surveillance. Furthermore, preclinical and early clinical studies have shown that PARP inhibitors and immune checkpoint inhibitors have synergistic antitumor activity and may provide an additional therapeutic option for patients in this population. In women with newly diagnosed ovarian, fallopian tube, or peritoneal cancer, we wish to assess the efficacy of frontline maintenance treatment with the PARP inhibitor rucaparib versus placebo following response to platinum-based chemotherapy (ATHENA-MONO), and to assess the combination of rucaparib plus nivolumab (a programmed death receptor 1 (PD-1)-blocking monoclonal antibody) versus rucaparib alone (ATHENA-COMBO). (1) Maintenance therapy with rucaparib monotherapy may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting. (2) The combination of nivolumab plus rucaparib may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting compared with rucaparib alone. ATHENA is an international, randomized, double-blind, phase III trial consisting of two independent comparisons (ATHENA-MONO and ATHENA-COMBO) in patients with newly diagnosed platinum-sensitive ovarian cancer. Patients are randomized 4:4:1:1 to the following: oral rucaparib+ intravenous nivolumab (arm A); oral rucaparib + intravenous placebo (arm B); oral placebo+ intravenous nivolumab (arm C); and oral placebo + intravenous placebo (arm D). The starting dose of rucaparib is 600 mg orally twice a day and nivolumab 480 mg intravenously every 4 weeks. ATHENA-MONO compares arm B with arm D to evaluate rucaparib monotherapy versus placebo, and ATHENA-COMBO evaluates arm A versus arm B to investigate the effects of rucaparib and nivolumab in combination versus rucaparib monotherapy. ATHENA-MONO and ATHENA-COMBO share a common treatment arm (arm B) but each comparison is independently powered. Patients ≥18 years of age with newly diagnosed advanced, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer who have achieved a response after completion of cytoreductive surgery and initial platinum-based chemotherapy are enrolled. No other prior treatment for ovarian cancer, other than the frontline platinum regimen, is permitted. The primary endpoint is investigator-assessed progression-free survival by Response Evaluation Criteria in Solid Tumors v1.1. Approximately 1000 patients have been enrolled and randomized. The trial completed accrual in 2020. While dependent on event rates, primary results of ATHENA-MONO are anticipated in early 2022 and results of ATHENA-COMBO are anticipated to mature at a later date. This trial is registered at clinicaltrials.gov (NCT03522246). BackgroundThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated substantial improvement in progression-free survival as monotherapy maintenance treatment in the frontline setting versus active surveillance. Furthermore, preclinical and early clinical studies have shown that PARP inhibitors and immune checkpoint inhibitors have synergistic antitumor activity and may provide an additional therapeutic option for patients in this population.Primary ObjectivesIn women with newly diagnosed ovarian, fallopian tube, or peritoneal cancer, we wish to assess the efficacy of frontline maintenance treatment with the PARP inhibitor rucaparib versus placebo following response to platinum-based chemotherapy (ATHENA–MONO), and to assess the combination of rucaparib plus nivolumab (a programmed death receptor 1 (PD-1)–blocking monoclonal antibody) versus rucaparib alone (ATHENA–COMBO).Study Hypothesis(1) Maintenance therapy with rucaparib monotherapy may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting. (2) The combination of nivolumab plus rucaparib may extend progression-free survival following standard treatment for ovarian cancer in the frontline setting compared with rucaparib alone.Trial DesignATHENA is an international, randomized, double-blind, phase III trial consisting of two independent comparisons (ATHENA–MONO and ATHENA–COMBO) in patients with newly diagnosed platinum-sensitive ovarian cancer. Patients are randomized 4:4:1:1 to the following: oral rucaparib+ intravenous nivolumab (arm A); oral rucaparib + intravenous placebo (arm B); oral placebo+ intravenous nivolumab (arm C); and oral placebo + intravenous placebo (arm D). The starting dose of rucaparib is 600 mg orally twice a day and nivolumab 480 mg intravenously every 4 weeks. ATHENA–MONO compares arm B with arm D to evaluate rucaparib monotherapy versus placebo, and ATHENA–COMBO evaluates arm A versus arm B to investigate the effects of rucaparib and nivolumab in combination versus rucaparib monotherapy. ATHENA–MONO and ATHENA–COMBO share a common treatment arm (arm B) but each comparison is independently powered.Major Inclusion/Exclusion CriteriaPatients ≥18 years of age with newly diagnosed advanced, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer who have achieved a response after completion of cytoreductive surgery and initial platinum-based chemotherapy are enrolled. No other prior treatment for ovarian cancer, other than the frontline platinum regimen, is permitted.Primary EndpointThe primary endpoint is investigator-assessed progression-free survival by Response Evaluation Criteria in Solid Tumors v1.1.Sample SizeApproximately 1000 patients have been enrolled and randomized.Estimated Dates for Completing Accrual and Presenting ResultsThe trial completed accrual in 2020. While dependent on event rates, primary results of ATHENA–MONO are anticipated in early 2022 and results of ATHENA–COMBO are anticipated to mature at a later date.Trial RegistrationThis trial is registered at clinicaltrials.gov (NCT03522246).
ArticleNumber	ijgc-2021-002933
Author	Monk, Bradley J O’Malley, David M Oaknin, Ana N Eskander, Ramez Wilson, Michelle K Grechko, Nikolay Fujiwara, Keiichi Hume, Stephanie McNeish, Iain A Coleman, Robert L Marmé, Frederik Shih, Danny Westin, Shannon N Oza, Amit M Goble, Sandra Herzog, Thomas J Lin, Kevin K Maloney, Lara Lorusso, Domenica Safra, Tamar Kristeleit, Rebecca S
AuthorAffiliation	Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona, USA US Oncology Research, The Woodlands, Texas, USA Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan Department of Cancer and Blood, Auckland City Hospital, Auckland, New Zealand Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, Ohio, USA Unità di Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori and MITO, MIlan, Italy Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Oncology Department, Tel Aviv Sourask
AuthorAffiliation_xml	– name: Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona, USA US Oncology Research, The Woodlands, Texas, USA Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan Department of Cancer and Blood, Auckland City Hospital, Auckland, New Zealand Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, Ohio, USA Unità di Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori and MITO, MIlan, Italy Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Oncology Department, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel Department of Ob/Gyn, University of Cincinnati Cancer Center, Cincinnati, Ohio, USA Gynecological Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Gynecologic Oncology, Rebecca and John Moores Cancer Center, University of California San Diego, La Jolla, California, USA Molecular Diagnostics, Clovis Oncology, Inc, Boulder, Colorado, USA Clinical Operations, Clovis Oncology, Inc, Boulder, Colorado, USA Biostatistics, Clovis Oncology, Inc, Boulder, Colorado, USA Clinical Development, Clovis Oncology, Ltd, Cambridge, Cambridgeshire, UK Clinical Development, Clovis Oncology, Inc, Boulder, Colorado, USA Department of Surgery and Cancer, Imperial College London, London, UK Department of Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK – name: 3 Department of Gynecologic Oncology , Saitama Medical University International Medical Center , Hidaka , Saitama , Japan – name: 9 Department of Gynecologic Oncology and Reproductive Medicine , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA – name: 16 Biostatistics , Clovis Oncology, Inc , Boulder , Colorado , USA – name: 18 Clinical Development , Clovis Oncology, Inc , Boulder , Colorado , USA – name: 13 Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Gynecologic Oncology, Rebecca and John Moores Cancer Center , University of California San Diego , La Jolla , California , USA – name: 12 Gynecological Oncology , National Center for Tumor Diseases (NCT) Heidelberg , Heidelberg , Germany – name: 15 Clinical Operations , Clovis Oncology, Inc , Boulder , Colorado , USA – name: 17 Clinical Development , Clovis Oncology, Ltd , Cambridge , Cambridgeshire , UK – name: 4 Department of Cancer and Blood , Auckland City Hospital , Auckland , New Zealand – name: 5 Division of Medical Oncology and Hematology , Princess Margaret Hospital Cancer Centre , Toronto , Ontario , Canada – name: 10 Oncology Department, Tel Aviv Sourasky Medical Center, Sackler School of Medicine , Tel Aviv University , Tel Aviv , Israel – name: 14 Molecular Diagnostics , Clovis Oncology, Inc , Boulder , Colorado , USA – name: 11 Department of Ob/Gyn , University of Cincinnati Cancer Center , Cincinnati , Ohio , USA – name: 19 Department of Surgery and Cancer , Imperial College London , London , UK – name: 20 Department of Oncology , Guy’s and St Thomas’ NHS Foundation Trust , London , UK – name: 2 US Oncology Research , The Woodlands , Texas , USA – name: 8 Unità di Ginecologia Oncologica , Fondazione IRCCS Istituto Nazionale dei Tumori and MITO , MIlan , Italy – name: 1 Arizona Oncology (US Oncology Network) , University of Arizona College of Medicine, Creighton University School of Medicine , Phoenix , Arizona , USA – name: 7 Division of Gynecologic Oncology , The Ohio State University, James Cancer Center , Columbus , Ohio , USA – name: 6 Medical Oncology Department , Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO) , Barcelona , Spain
Author_xml	– sequence: 1 givenname: Bradley J surname: Monk fullname: Monk, Bradley J email: bradley.monk@usoncology.com organization: Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, Arizona, USA – sequence: 2 givenname: Robert L surname: Coleman fullname: Coleman, Robert L organization: US Oncology Research, The Woodlands, Texas, USA – sequence: 3 givenname: Keiichi orcidid: 0000-0002-7388-0243 surname: Fujiwara fullname: Fujiwara, Keiichi organization: Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan – sequence: 4 givenname: Michelle K surname: Wilson fullname: Wilson, Michelle K organization: Department of Cancer and Blood, Auckland City Hospital, Auckland, New Zealand – sequence: 5 givenname: Amit M surname: Oza fullname: Oza, Amit M organization: Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada – sequence: 6 givenname: Ana surname: Oaknin fullname: Oaknin, Ana organization: Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain – sequence: 7 givenname: David M surname: O’Malley fullname: O’Malley, David M organization: Division of Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, Ohio, USA – sequence: 8 givenname: Domenica surname: Lorusso fullname: Lorusso, Domenica organization: Unità di Ginecologia Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori and MITO, MIlan, Italy – sequence: 9 givenname: Shannon N orcidid: 0000-0002-1922-0156 surname: Westin fullname: Westin, Shannon N organization: Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 10 givenname: Tamar surname: Safra fullname: Safra, Tamar organization: Oncology Department, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 11 givenname: Thomas J surname: Herzog fullname: Herzog, Thomas J organization: Department of Ob/Gyn, University of Cincinnati Cancer Center, Cincinnati, Ohio, USA – sequence: 12 givenname: Frederik surname: Marmé fullname: Marmé, Frederik organization: Gynecological Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany – sequence: 13 givenname: Ramez surname: N Eskander fullname: N Eskander, Ramez organization: Department of Obstetrics, Gynecology, and Reproductive Sciences, Division of Gynecologic Oncology, Rebecca and John Moores Cancer Center, University of California San Diego, La Jolla, California, USA – sequence: 14 givenname: Kevin K surname: Lin fullname: Lin, Kevin K organization: Molecular Diagnostics, Clovis Oncology, Inc, Boulder, Colorado, USA – sequence: 15 givenname: Danny surname: Shih fullname: Shih, Danny organization: Clinical Operations, Clovis Oncology, Inc, Boulder, Colorado, USA – sequence: 16 givenname: Sandra surname: Goble fullname: Goble, Sandra organization: Biostatistics, Clovis Oncology, Inc, Boulder, Colorado, USA – sequence: 17 givenname: Nikolay surname: Grechko fullname: Grechko, Nikolay organization: Clinical Development, Clovis Oncology, Ltd, Cambridge, Cambridgeshire, UK – sequence: 18 givenname: Stephanie surname: Hume fullname: Hume, Stephanie organization: Clinical Development, Clovis Oncology, Inc, Boulder, Colorado, USA – sequence: 19 givenname: Lara surname: Maloney fullname: Maloney, Lara organization: Clinical Development, Clovis Oncology, Inc, Boulder, Colorado, USA – sequence: 20 givenname: Iain A surname: McNeish fullname: McNeish, Iain A organization: Department of Surgery and Cancer, Imperial College London, London, UK – sequence: 21 givenname: Rebecca S surname: Kristeleit fullname: Kristeleit, Rebecca S organization: Department of Oncology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34593565$$D View this record in MEDLINE/PubMed
BookMark	eNp9Ustu1DAUDaiIPmDPCnnZSg21kziTdIFUqjIdqe1sisTOcpybxoNjTx1nRmXFP_CHfAl3mlIVJLpKopyX7jm70ZZ1FqLoHaMfGEvzI724UXFCExZTmpRp-jLaYTzhMcvSYgvfaVbERcm-bke7fb-glJYJLV9H22nGy5TnfOfF9sn1-dnVCdmfzqdxShN6dHY1nV_HbpXxg2MiiZe2dp3-DvUhWbayBzKbzUjwWhoSHIGVNIMMQPyg5FJ6XRHZk85ZF1rwcnlH9keHXz9-Xs6v5gcE9Z6AtSXKdZW2MmhnyVqHlli9cmboZPWEezq__LQho7bUNoCVVgHGABk6sIE0zhi31vaGNN7ZYLQFsjQoaocurjB2TVQL3WMq9HUrTCDRfyPl30SvGml6ePvw3Iu-fD67Pj2PL-bT2enJRVxxvHDc1BLynNWyYsCqJE0rTiGHgtGKNkVBJU9lSrMqAz6ZlM0k51CqnGcl3j6XVKV70cdRdzlUHdQKw3tpxNLrTvo74aQWf_-xuhU3biWKPM8LxlFg_0HAu9sB-iA63SswRlpwQy8SPikm6FskCH3_1OvR5E_9CKAjQHnX9x6aRwijYrMwsVmY2CxMjAtDSv4PRelwXx6m1eY5YjYS184E8P03M6zBixakCS2C8EB4svs1swS_cNKUbWjHIw2wlJVGRq80YGO19qCCqJ1-zvNwJFfdQizc4C1W-3_4b7D-Cec
CitedBy_id	crossref_primary_10_1097_COC_0000000000001024 crossref_primary_10_1016_j_omto_2023_02_006 crossref_primary_10_1002_pros_24721 crossref_primary_10_3390_cancers14225633 crossref_primary_10_1186_s12916_024_03826_w crossref_primary_10_3390_cancers15225386 crossref_primary_10_1038_s41568_022_00503_z crossref_primary_10_1016_j_annonc_2023_05_005 crossref_primary_10_3389_fimmu_2023_1061761 crossref_primary_10_1158_1078_0432_CCR_22_3335 crossref_primary_10_2147_CMAR_S294080 crossref_primary_10_1093_jjco_hyad171 crossref_primary_10_1111_jcmm_18115 crossref_primary_10_1097_CM9_0000000000003125 crossref_primary_10_1016_j_ctarc_2022_100677 crossref_primary_10_1016_j_lfs_2022_120827 crossref_primary_10_1016_j_esmoop_2024_104119 crossref_primary_10_1016_j_critrevonc_2025_104704 crossref_primary_10_1017_erm_2023_3 crossref_primary_10_3389_fmed_2022_799145 crossref_primary_10_3390_ijms241511890 crossref_primary_10_1136_ijgc_2023_004995 crossref_primary_10_3390_cancers14194621 crossref_primary_10_1055_a_2622_0684 crossref_primary_10_7759_cureus_65638 crossref_primary_10_1177_17588359231192397 crossref_primary_10_1186_s13048_024_01507_z crossref_primary_10_3390_cells14130995 crossref_primary_10_20935_AcadOnco7784 crossref_primary_10_3390_cancers17050786 crossref_primary_10_1016_j_critrevonc_2023_104229 crossref_primary_10_1016_j_biopha_2024_116733 crossref_primary_10_1177_17588359251343973 crossref_primary_10_1007_s11523_023_00970_w crossref_primary_10_3390_cancers17020271 crossref_primary_10_3389_fonc_2024_1387281 crossref_primary_10_3390_biom13101480 crossref_primary_10_1016_j_ijgc_2025_101931 crossref_primary_10_1016_j_bcp_2023_115724 crossref_primary_10_1038_s41416_024_02776_7 crossref_primary_10_3390_ijms26062545 crossref_primary_10_1016_j_ygyno_2024_05_014 crossref_primary_10_1038_s41420_025_02418_8 crossref_primary_10_1111_jog_15730 crossref_primary_10_3390_ijms25021263 crossref_primary_10_3390_cancers14061420 crossref_primary_10_1136_ijgc_2022_004149
Cites_doi	10.1200/JCO.21.00306 10.1056/NEJMoa1911361 10.1056/NEJMoa1910962 10.1056/NEJMoa1103799 10.1016/j.ygyno.2018.08.036 10.1016/S0140-6736(17)32440-6 10.1016/j.ygyno.2020.06.025 10.18632/oncotarget.7277 10.1200/JCO.19.01009 10.1056/NEJMoa1104390 10.1056/NEJMoa1810858
ContentType	Journal Article
Copyright	IGCS and ESGO 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. 2021 IGCS and ESGO 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. IGCS and ESGO 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. 2021
Copyright_xml	– notice: IGCS and ESGO 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. – notice: 2021 IGCS and ESGO 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. – notice: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology. – notice: IGCS and ESGO 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. 2021
DBID	9YT ACMMV 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM
DOI	10.1136/ijgc-2021-002933
DatabaseName	BMJ Open Access Journals BMJ Journals:Open Access ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1525-1438
EndPage	1594
ExternalDocumentID	PMC8666815 34593565 10_1136_ijgc_2021_002933 00009577-202112000-00013 S1048891X25001008 ijgc
Genre	Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: Clovis Oncology funderid: http://dx.doi.org/10.13039/100014487 – fundername: ;
GroupedDBID	--- .Z2 0R~ 1OC 36B 53G 5GY 5VS 7X7 8FI 8FJ 9YT AAHLL AARTV AAXUO ABBUW ABJNI ABUWG ABXVJ ACDDN ACEWG ACGFO ACGFS ACMMV ACWDW ACWRI ACXNZ AENEX AFEBI AFKRA AGINI AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BQLVK CCPQU CS3 CXRWF E.X EX3 F5P FDB FL- FYUFA HAJ HMCUK HZ~ IHE IN~ KD2 L-C LH4 M41 O9- OHYEH OVD OXXIT P2P RMJ ROL S4S TEORI UKHRP V2I W3M WOW YUY .3N 29J 31~ 4.4 6I. 8-1 AAFTH AAKAS AALRI ABZAD ACXQS ADZCM AFBPY AFTRI AFZJQ AHEFC AIZYK AJAOE AJNYG AWKKM BFHJK CAG CO8 COF DC6 DCZOG EBS EJD FZ0 HZI LW6 OCUKA ORVUJ OUVQU UDS W99 X3V X3W AAYWO AAYXX ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP AMRAJ CITATION PHGZM CGR CUY CVF ECM EIF NPM 7X8 5PM
ID	FETCH-LOGICAL-b5293-fdae661dab1e1b233b50e6e810b0f880a53a304b4e5779f765e9c65490096a0c3
ISICitedReferencesCount	62
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00009577-202112000-00013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1048-891X 1525-1438
IngestDate	Tue Nov 04 01:59:44 EST 2025 Sun Sep 28 02:56:00 EDT 2025 Mon Jul 21 06:04:12 EDT 2025 Sat Nov 29 07:44:05 EST 2025 Tue Nov 18 20:55:45 EST 2025 Fri May 16 03:51:37 EDT 2025 Sat Feb 01 16:07:31 EST 2025 Thu Apr 24 22:49:44 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	12
Keywords	BRCA2 protein ovarian neoplasms homologous recombination BRCA1 protein
Language	English
License	This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. http://creativecommons.org/licenses/by-nc-nd/4.0 IGCS and ESGO 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-b5293-fdae661dab1e1b233b50e6e810b0f880a53a304b4e5779f765e9c65490096a0c3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Present affiliation: The present affiliation of Frederik Marmé is: Department of Obstetrics and Gynecology, Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Mannheim, Germany
ORCID	0000-0002-1922-0156 0000-0002-7388-0243
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC8666815
PMID	34593565
PQID	2578776582
PQPubID	23479
PageCount	6
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_8666815 proquest_miscellaneous_2578776582 pubmed_primary_34593565 crossref_primary_10_1136_ijgc_2021_002933 crossref_citationtrail_10_1136_ijgc_2021_002933 wolterskluwer_health_00009577-202112000-00013 elsevier_sciencedirect_doi_10_1136_ijgc_2021_002933 bmj_journals_10_1136_ijgc_2021_002933
PublicationCentury	2000
PublicationDate	2021-December-01
PublicationDateYYYYMMDD	2021-12-01
PublicationDate_xml	– month: 12 year: 2021 text: 2021-December-01 day: 01
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: BMA House, Tavistock Square, London, WC1H 9JR
PublicationTitle	International journal of gynecological cancer
PublicationTitleAbbrev	Int J Gynecol Cancer
PublicationTitleAlternate	Int J Gynecol Cancer
PublicationYear	2021
Publisher	BMJ Publishing Group Ltd Elsevier Inc by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology BMJ Publishing Group
Publisher_xml	– name: BMJ Publishing Group Ltd – name: Elsevier Inc – name: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology – name: BMJ Publishing Group
References	Moore, Colombo, Scambia (R6) 2018; 379 Strickland, Howitt, Shukla (R13) 2016; 7 Tewari, Burger, Enserro (R5) 2019; 37 Ledermann, Colombo, Oza (R11) 2020; 159 Perren, Swart, Pfisterer (R3) 2011; 365 González Martín, Oza, Embleton (R4) 2019; 152 Burger, Brady, Bookman (R2) 2011; 365 Coleman, Oza, Lorusso (R9) 2017; 390 Moore, Bookman, Sehouli (R12) 2021; 39 González-Martín, Pothuri, Vergote (R15) 2019; 381 Ray-Coquard, Pautier, Pignata (R7) 2019; 381 Burger, Brady, Bookman (bb0015) 2011; 365 Clovis Oncology, Inc (bb0045) 2020 Coleman, Oza, Lorusso (bb0050) 2017; 390 Bristol-Myers Squibb Company (bb0055) 2020 Strickland, Howitt, Shukla (bb0070) 2016; 7 Moore, Colombo, Scambia (bb0035) 2018; 379 Landen, Molinero, Sehouli (bb0075) 2021 González Martín, Oza, Embleton (bb0025) 2019; 152 Ray-Coquard, Pautier, Pignata (bb0040) 2019; 381 Perren, Swart, Pfisterer (bb0020) 2011; 365 Moore, Bookman, Sehouli (bb0065) 2021; 39 Tewari, Burger, Enserro (bb0030) 2019; 37 Ferlay, Ervik, Lam (bb0010) 2020 Ledermann, Colombo, Oza (bb0060) 2020; 159 González-Martín, Pothuri, Vergote (bb0080) 2019; 381 Coleman (10.1136/ijgc-2021-002933_bb0050) 2017; 390 Moore (10.1136/ijgc-2021-002933_bb0035) 2018; 379 Ledermann (10.1136/ijgc-2021-002933_bb0060) 2020; 159 González Martín (10.1136/ijgc-2021-002933_bb0025) 2019; 152 Tewari (10.1136/ijgc-2021-002933_bb0030) 2019; 37 Ferlay (10.1136/ijgc-2021-002933_bb0010) 2020 Moore (10.1136/ijgc-2021-002933_bb0065) 2021; 39 Landen (10.1136/ijgc-2021-002933_bb0075) 2021 Perren (10.1136/ijgc-2021-002933_bb0020) 2011; 365 Ray-Coquard (10.1136/ijgc-2021-002933_bb0040) 2019; 381 Burger (10.1136/ijgc-2021-002933_bb0015) 2011; 365 Bristol-Myers Squibb Company (10.1136/ijgc-2021-002933_bb0055) 2020 Strickland (10.1136/ijgc-2021-002933_bb0070) 2016; 7 González-Martín (10.1136/ijgc-2021-002933_bb0080) 2019; 381 Clovis Oncology, Inc (10.1136/ijgc-2021-002933_bb0045) 2020
References_xml	– volume: 39 start-page: 1842 year: 2021 ident: R12 article-title: Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39) publication-title: J Clin Oncol doi: 10.1200/JCO.21.00306 – volume: 381 start-page: 2416 year: 2019 ident: R7 article-title: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1911361 – volume: 381 start-page: 2391 year: 2019 ident: R15 article-title: Niraparib in patients with newly diagnosed advanced ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1910962 – volume: 365 start-page: 2484 year: 2011 ident: R3 article-title: A phase 3 trial of bevacizumab in ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1103799 – volume: 152 start-page: 53 year: 2019 ident: R4 article-title: Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2018.08.036 – volume: 390 start-page: 1949 year: 2017 ident: R9 article-title: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(17)32440-6 – volume: 159 start-page: 13 year: 2020 ident: R11 article-title: Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 JAVELIN ovarian 100 trial publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2020.06.025 – volume: 7 start-page: 13587 year: 2016 ident: R13 article-title: Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer publication-title: Oncotarget doi: 10.18632/oncotarget.7277 – volume: 37 start-page: 2317 year: 2019 ident: R5 article-title: Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.01009 – volume: 365 start-page: 2473 year: 2011 ident: R2 article-title: Incorporation of bevacizumab in the primary treatment of ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1104390 – volume: 379 start-page: 2495 year: 2018 ident: R6 article-title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1810858 – volume: 381 start-page: 2416 year: 2019 end-page: 28 ident: bb0040 article-title: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer publication-title: N Engl J Med – year: 2020 ident: bb0055 – volume: 37 start-page: 2317 year: 2019 end-page: 28 ident: bb0030 article-title: Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer publication-title: J Clin Oncol – volume: 390 start-page: 1949 year: 2017 end-page: 61 ident: bb0050 article-title: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet – volume: 7 start-page: 13587 year: 2016 end-page: 98 ident: bb0070 article-title: Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer publication-title: Oncotarget – year: 2020 ident: bb0045 – year: 2021 ident: bb0075 publication-title: Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: exploratory analyses. Presented at: 2021 Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting – volume: 381 start-page: 2391 year: 2019 end-page: 402 ident: bb0080 article-title: Niraparib in patients with newly diagnosed advanced ovarian cancer publication-title: N Engl J Med – volume: 379 start-page: 2495 year: 2018 end-page: 505 ident: bb0035 article-title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer publication-title: N Engl J Med – year: 2020 ident: bb0010 – volume: 39 start-page: 1842 year: 2021 end-page: 55 ident: bb0065 article-title: Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39) publication-title: J Clin Oncol – volume: 365 start-page: 2473 year: 2011 end-page: 83 ident: bb0015 article-title: Incorporation of bevacizumab in the primary treatment of ovarian cancer publication-title: N Engl J Med – volume: 152 start-page: 53 year: 2019 end-page: 60 ident: bb0025 article-title: Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer publication-title: Gynecol Oncol – volume: 365 start-page: 2484 year: 2011 end-page: 96 ident: bb0020 article-title: A phase 3 trial of bevacizumab in ovarian cancer publication-title: N Engl J Med – volume: 159 start-page: 13 year: 2020 end-page: 14 ident: bb0060 article-title: Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 JAVELIN ovarian 100 trial publication-title: Gynecol Oncol – volume: 159 start-page: 13 year: 2020 ident: 10.1136/ijgc-2021-002933_bb0060 article-title: Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 JAVELIN ovarian 100 trial publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2020.06.025 – year: 2020 ident: 10.1136/ijgc-2021-002933_bb0055 – volume: 381 start-page: 2391 year: 2019 ident: 10.1136/ijgc-2021-002933_bb0080 article-title: Niraparib in patients with newly diagnosed advanced ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1910962 – volume: 39 start-page: 1842 year: 2021 ident: 10.1136/ijgc-2021-002933_bb0065 article-title: Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39) publication-title: J Clin Oncol doi: 10.1200/JCO.21.00306 – year: 2020 ident: 10.1136/ijgc-2021-002933_bb0010 – year: 2020 ident: 10.1136/ijgc-2021-002933_bb0045 – volume: 7 start-page: 13587 year: 2016 ident: 10.1136/ijgc-2021-002933_bb0070 article-title: Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer publication-title: Oncotarget doi: 10.18632/oncotarget.7277 – volume: 365 start-page: 2473 year: 2011 ident: 10.1136/ijgc-2021-002933_bb0015 article-title: Incorporation of bevacizumab in the primary treatment of ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1104390 – volume: 365 start-page: 2484 year: 2011 ident: 10.1136/ijgc-2021-002933_bb0020 article-title: A phase 3 trial of bevacizumab in ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1103799 – volume: 381 start-page: 2416 year: 2019 ident: 10.1136/ijgc-2021-002933_bb0040 article-title: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1911361 – volume: 390 start-page: 1949 year: 2017 ident: 10.1136/ijgc-2021-002933_bb0050 article-title: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(17)32440-6 – year: 2021 ident: 10.1136/ijgc-2021-002933_bb0075 – volume: 152 start-page: 53 year: 2019 ident: 10.1136/ijgc-2021-002933_bb0025 article-title: Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2018.08.036 – volume: 37 start-page: 2317 year: 2019 ident: 10.1136/ijgc-2021-002933_bb0030 article-title: Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer publication-title: J Clin Oncol doi: 10.1200/JCO.19.01009 – volume: 379 start-page: 2495 year: 2018 ident: 10.1136/ijgc-2021-002933_bb0035 article-title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1810858
SSID	ssj0009209
Score	2.5370224
Snippet	BackgroundThe optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors... The optimal treatment strategy for women with newly diagnosed ovarian cancer has yet to be determined. Poly(ADP-ribose) polymerase (PARP) inhibitors have...
SourceID	pubmedcentral proquest pubmed crossref wolterskluwer elsevier bmj
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1589
SubjectTerms	Antineoplastic Combined Chemotherapy Protocols - administration & dosage BRCA1 protein BRCA2 protein Carcinoma, Ovarian Epithelial - drug therapy Clinical Trial Double-Blind Method Female homologous recombination Humans Indoles - administration & dosage Maintenance Chemotherapy - methods Nivolumab - administration & dosage ovarian neoplasms Ovarian Neoplasms - drug therapy Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage
Title	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
URI	https://ijgc.bmj.com/content/early/2021/09/29/ijgc-2021-002933.full https://dx.doi.org/10.1136/ijgc-2021-002933 https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00009577-202112000-00013 https://www.ncbi.nlm.nih.gov/pubmed/34593565 https://www.proquest.com/docview/2578776582 https://pubmed.ncbi.nlm.nih.gov/PMC8666815
Volume	31
WOSCitedRecordID	wos00009577-202112000-00013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1525-1438 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0009209 issn: 1048-891X databaseCode: 7X7 dateStart: 20180101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1525-1438 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0009209 issn: 1048-891X databaseCode: BENPR dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF56IISEEDfhqBYJUKOwanzbvLVVekhtUqEU5W21ttet28YOSZMWfj2zhzcOhQoeeLEq13u0M9_OsXMg9D7jLijRaUhiK0uJmwURCUPLJbaXZUHo8cyWF-1fD4JuNxwMoqOlZVrlwswugqIIr6-j0X8lNbwDYovU2X8gt5kUXsDPQHR4Atnh-VeE3-zvdbqb0vzv7RIHFDWYq9Pd7fVJOXM9MP1VgjMIqbQc5j-Ut3N0CuKstb-_31J9PEAl1YXAeQvIz0Szwlg0pYG_QydtyTgBtRqBk7knHAwyWt18rmLcwfZWXCZ9vkUuD0QW10Zv9w631HCYn4kKFoXMZJhHwWfAruWVjPoUFRekbjwSYXzFdEiEJE5bwH1DszNYuZzBHuD0SsRU47oSvugFrdXOOPle8MRIg9pAGZVcnCswsFQcpMa_vl1ecO1GVmHqLeNP35me5VdsrLLueJ4np3nNzzWZJy6I2xPtcNYeGNuqRbNooWF7RLSRVzL1N--0pHGsOqLsmtywPNVI6aZAkx138rOThMilxS2qqhyyWDu826M7xwcHtN8Z9D-OvhHRVk2EH-geM8to1Q68CI791a1O9-jLvC61ioIy261u8h1_49dFQfuKh2d_0t9u2mc3w4wfXJUiBGRyLjNAanpc_xF6qA0wvKmA8xgt8eIJuneoQ0ye3llRPInXK_RszLHT_IwZnuPmE5aowYAaLFGDL0tcoQYbGGA2wTXU4PUaZpoYZqt9mhe4hhgsEIMNYsxIiZemnHeOFmzQgg1asEELXkQLrqNFrKrRghXTP0PHO53-9h7RrVJI7AFtSJYyDpp2ymKLW7HtOLHX5j4PrXbczkBEM89hTtuNXe4FQZQFvsejxPfcSLgwWDtxnqOVoiz4S4TdzG4naRYnLAHtPvQZS6Is8yM_SWInbqcN9AHYgGpwTqj0Ijg-FexCBbtQxS4NtFExCk10vwHR9ubilhFNM2Kkau3c8q1T8R7VtoKyASgg55ZR7yo2pSBGxd0oK3g5nVCpucC_JbQb6IViW7MHx_UiBwzfBgoWGNp8IEr0L_6myE9lqf7Q9_3QgpFkgfWpSnKn0kIHikiYWVWVD8t59Rf7fI3uzw-jN2jlcjzlb9HdZHaZT8ZraDkYBPIZrmnM_wRB2WvQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ATHENA+%28GOG-3020%2FENGOT-ov45%29%3A+a+randomized%2C+phase+III+trial+to+evaluate+rucaparib+as+monotherapy+%28ATHENA-MONO%29+and+rucaparib+in+combination+with+nivolumab+%28ATHENA-COMBO%29+as+maintenance+treatment+following+frontline+platinum-based+chemotherapy+in+ovarian+cancer&rft.jtitle=International+journal+of+gynecological+cancer&rft.au=Monk%2C+Bradley+J&rft.au=Coleman%2C+Robert+L&rft.au=Fujiwara%2C+Keiichi&rft.au=Wilson%2C+Michelle+K&rft.date=2021-12-01&rft.issn=1525-1438&rft.eissn=1525-1438&rft.volume=31&rft.issue=12&rft.spage=1589&rft_id=info:doi/10.1136%2Fijgc-2021-002933&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1048-891X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1048-891X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1048-891X&client=summon